FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M

First Page		Document Content
Date: 2016-04-19 06:39:33 Clinical medicine Medicine Lung cancer Biology KRAS Non-small-cell lung carcinoma Biomarker Ras subfamily FASN Fatty acid synthase		FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M Add to Reading List Source URL: www.3vbio.com Download Document from Source Website File Size: 997,69 KB Share Document on Facebook